{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:39:53Z","timestamp":1792589993001,"version":"4.5.0"},"reference-count":30,"publisher":"MyJove Corporation","issue":"231","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/70167","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:00:13Z","timestamp":1778626813000},"source":"Crossref","is-referenced-by-count":0,"title":["Development and Validation of a Rapid LC-MS\/MS Method for Carfilzomib Quantification in Plasma from Multiple Myeloma Patients"],"prefix":"10.3791","author":[{"given":"Zhengyan","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liya","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanxing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouhong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"8","key":"ref1","first-page":"900","type":"journal-article","article-title":"Research progress in proteasome inhibitor resistance to multiple myeloma","volume":"46","author":"Wu","year":"2021","unstructured":"Wu, J. Liu, J. Research progress in proteasome inhibitor resistance to multiple myeloma. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 46 (8), 900-908 (2021).","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"issue":"12","key":"ref2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","type":"journal-article","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15 (12), e538-548 (2014).","journal-title":"Lancet Oncol"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2017.1.498","type":"journal-article","article-title":"Management of multiple myeloma in the newly diagnosed patient","volume":"2017","author":"Mateos","year":"2017","unstructured":"Mateos, M. V., San Miguel, J. F. Management of multiple myeloma in the newly diagnosed patient. Hematology Am Soc Hematol Educ Program. 2017 (1), 498-507 (2017).","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.clml.2017.02.018","type":"journal-article","article-title":"High-risk multiple myeloma: Definition and management","volume":"17s","author":"Joseph","year":"2017","unstructured":"Joseph, N. S., Gentili, S., Kaufman, J. L., Lonial, S., Nooka, A. K. High-risk multiple myeloma: Definition and management. Clin Lymphoma Myeloma Leuk. 17s S80-s87 (2017).","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"20","key":"ref5","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1182\/blood-2015-01-613596","type":"journal-article","article-title":"Introduction to a series of reviews on multiple myeloma","volume":"125","author":"San Miguel","year":"2015","unstructured":"San Miguel, J. F. Introduction to a series of reviews on multiple myeloma. Blood. 125 (20), 3039-3040 (2015).","journal-title":"Blood"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/oncolo\/oyad306","type":"journal-article","article-title":"Perspectives on the treatment of multiple myeloma","volume":"29","author":"Rafae","year":"2024","unstructured":"Rafae, A., Van Rhee, F., Al Hadidi, S. Perspectives on the treatment of multiple myeloma. Oncologist. 29 (3), 200-212 (2024).","journal-title":"Oncologist"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"23785","DOI":"10.1002\/jcp.28947","type":"journal-article","article-title":"Identification of key candidate genes and pathways in multiple myeloma by integrated bioinformatics analysis","volume":"234","author":"Yan","year":"2019","unstructured":"Yan, H. et al. Identification of key candidate genes and pathways in multiple myeloma by integrated bioinformatics analysis. J Cell Physiol. 234 (12), 23785-23797 (2019).","journal-title":"J Cell Physiol"},{"issue":"5","key":"ref8","first-page":"1576","type":"journal-article","article-title":"Research Progress on Molecular Mechanisms of Resistance to Bortezomib in Multiple Myeloma-Review","volume":"25","author":"Shi","year":"2017","unstructured":"Shi, L. L., Zhai, Y. P. Research Progress on Molecular Mechanisms of Resistance to Bortezomib in Multiple Myeloma-Review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 25 (5), 1576-1579 (2017).","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"5","key":"ref9","first-page":"1584","type":"journal-article","article-title":"Research Progress on Mechanism of Bortezomib Resistance in Multiple Myeloma","volume":"31","author":"Wang","year":"2023","unstructured":"Wang, Y. R., Ma, Y. P. Research Progress on Mechanism of Bortezomib Resistance in Multiple Myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 31 (5), 1584-1587 (2023).","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","type":"journal-article","article-title":"Nccn guidelines\u00ae insights: Multiple myeloma, version 3.2022","volume":"20","author":"Callander","year":"2022","unstructured":"Callander, N. S. et al. Nccn guidelines\u00ae insights: Multiple myeloma, version 3.2022. J Natl Compr Canc Netw. 20 (1), 8-19 (2022).","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","type":"journal-article","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with imids and bortezomib: A multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","unstructured":"Kumar, S. K. et al. Risk of progression and survival in multiple myeloma relapsing after therapy with imids and bortezomib: A multicenter international myeloma working group study. Leukemia. 26 (1), 149-157 (2012).","journal-title":"Leukemia"},{"issue":"9","key":"ref12","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","type":"journal-article","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","unstructured":"Kuhn, D. J. et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 110 (9), 3281-3290 (2007).","journal-title":"Blood"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","type":"journal-article","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","unstructured":"Moreau, P. et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study. Lancet Oncol. 12 (5), 431-440 (2011).","journal-title":"Lancet Oncol"},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1023\/A:1007669411738","type":"journal-article","article-title":"Bioanalytical method validation--a revisit with a decade of progress","volume":"17","author":"Shah","year":"2000","unstructured":"Shah, V. P. et al. Bioanalytical method validation--a revisit with a decade of progress. Pharm Res. 17 (12), 1551-1557 (2000).","journal-title":"Pharm Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"465459","DOI":"10.1016\/j.chroma.2024.465459","type":"journal-article","article-title":"Advances and challenges in non-targeted analysis: An insight into sample preparation and detection by liquid chromatography-mass spectrometry","volume":"1737","author":"Mandal","year":"2024","unstructured":"Mandal, V., Ajabiya, J., Khan, N., Tekade, R. K., Sengupta, P. Advances and challenges in non-targeted analysis: An insight into sample preparation and detection by liquid chromatography-mass spectrometry. J Chromatogr A. 1737 465459 (2024).","journal-title":"J Chromatogr A"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-1-4615-9546-5_35","type":"journal-article","article-title":"Enzyme-linked immunosorbent assays for human tissue kallikrein and analysis of immunoreactive kallikrein in the plasma by them","volume":"247b","author":"Kizuki","year":"1989","unstructured":"Kizuki, K. et al. Enzyme-linked immunosorbent assays for human tissue kallikrein and analysis of immunoreactive kallikrein in the plasma by them. Adv Exp Med Biol. 247b 211-216 (1989).","journal-title":"Adv Exp Med Biol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"114823","DOI":"10.1016\/j.jpba.2022.114823","type":"journal-article","article-title":"Comparison of methods for quantitative analysis of ranibizumab and bevacizumab in human plasma using various bioanalytical techniques, including microfluidic immunoassay, triple quadrupole, and high-resolution liquid chromatography-tandem mass spectrometry approaches","volume":"217","author":"Delguidice","year":"2022","unstructured":"Delguidice, C. E., Ismaiel, O. A., Mylott, W. R., Jr., Halquist, M. S. Comparison of methods for quantitative analysis of ranibizumab and bevacizumab in human plasma using various bioanalytical techniques, including microfluidic immunoassay, triple quadrupole, and high-resolution liquid chromatography-tandem mass spectrometry approaches. J Pharm Biomed Anal. 217 114823 (2022).","journal-title":"J Pharm Biomed Anal"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-020-00381-4","type":"journal-article","article-title":"Carfilzomib-associated renal toxicity is common and unpredictable: A comprehensive analysis of 114 multiple myeloma patients","volume":"10","author":"Fotiou","year":"2020","unstructured":"Fotiou, D. et al. Carfilzomib-associated renal toxicity is common and unpredictable: A comprehensive analysis of 114 multiple myeloma patients. Blood Cancer J. 10 (11), 109 (2020).","journal-title":"Blood Cancer J"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"645678","DOI":"10.3389\/fcvm.2021.645678","type":"journal-article","article-title":"Effects of carfilzomib therapy on left ventricular function in multiple myeloma patients","volume":"8","author":"Mingrone","year":"2021","unstructured":"Mingrone, G. et al. Effects of carfilzomib therapy on left ventricular function in multiple myeloma patients. Front Cardiovasc Med. 8 645678 (2021).","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","type":"journal-article","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","unstructured":"Stewart, A. K. et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 372 (2), 142-152 (2015).","journal-title":"N Engl J Med"},{"issue":"6","key":"ref21","first-page":"1887","type":"journal-article","article-title":"[efficacy and safety of carfilzomib in the treatment of multiple myeloma\uff1aa systematic evaluation]","volume":"27","author":"Luo","year":"2019","unstructured":"Luo, T., Xia, H. L. [efficacy and safety of carfilzomib in the treatment of multiple myeloma\uff1aa systematic evaluation]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 27 (6), 1887-1893 (2019).","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000519687","type":"journal-article","article-title":"Evaluation of cardiac adverse events associated with carfilzomib using a japanese real-world database","volume":"100","author":"Nakao","year":"2022","unstructured":"Nakao, S. et al. Evaluation of cardiac adverse events associated with carfilzomib using a japanese real-world database. Oncology. 100 (1), 60-64 (2022).","journal-title":"Oncology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jpba.2017.08.048","type":"journal-article","article-title":"Quantitative determination of carfilzomib in mouse plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study","volume":"146","author":"Min","year":"2017","unstructured":"Min, J. S. et al. Quantitative determination of carfilzomib in mouse plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. J Pharm Biomed Anal. 146 341-346 (2017).","journal-title":"J Pharm Biomed Anal"},{"issue":"10","key":"ref24","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1124\/dmd.111.039164","type":"journal-article","article-title":"Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats","volume":"39","author":"Yang","year":"2011","unstructured":"Yang, J. et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos. 39 (10), 1873-1882 (2011).","journal-title":"Drug Metab Dispos"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"6139928","DOI":"10.1155\/2024\/6139928","type":"journal-article","article-title":"A simple and rapid lc-ms\/ms method for the quantification of nirmatrelvir\/ritonavir in plasma of patients with covid-19","volume":"2024","author":"Zhu","year":"2024","unstructured":"Zhu, X. et al. A simple and rapid lc-ms\/ms method for the quantification of nirmatrelvir\/ritonavir in plasma of patients with covid-19. Int J Anal Chem. 2024 6139928 (2024).","journal-title":"Int J Anal Chem"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","type":"journal-article","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"Kang","year":"2009","unstructured":"Kang, J. S., Lee, M. H. Overview of therapeutic drug monitoring. Korean J Intern Med. 24 (1), 1-10 (2009).","journal-title":"Korean J Intern Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.clinbiochem.2020.03.004","type":"journal-article","article-title":"After another decade: Lc-ms\/ms became routine in clinical diagnostics","volume":"82","author":"Seger","year":"2020","unstructured":"Seger, C., Salzmann, L. After another decade: Lc-ms\/ms became routine in clinical diagnostics. Clin Biochem. 82 2-11 (2020).","journal-title":"Clin Biochem"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.02.008","type":"journal-article","article-title":"Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review","volume":"125","author":"Mushtaq","year":"2018","unstructured":"Mushtaq, A. et al. Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review. Crit Rev Oncol Hematol. 125 1-11 (2018).","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"20406207241292517","DOI":"10.1177\/20406207241292517","type":"journal-article","article-title":"A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma","volume":"15","author":"Smrdel","year":"2024","unstructured":"Smrdel, L., Locatelli, I., Zver, S., Gobec, M. A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma. Ther Adv Hematol. 15 20406207241292517 (2024).","journal-title":"Ther Adv Hematol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/164_2015_26","type":"journal-article","article-title":"Pharmacokinetics in drug discovery: An exposure-centred approach to optimising and predicting drug efficacy and safety","volume":"232","author":"Reichel","year":"2016","unstructured":"Reichel, A., Lienau, P. Pharmacokinetics in drug discovery: An exposure-centred approach to optimising and predicting drug efficacy and safety. Handb Exp Pharmacol. 232 235-260 (2016).","journal-title":"Handb Exp Pharmacol"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/t\/70167\/development-validation-rapid-lc-msms-method-for-carfilzomib","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:50:37Z","timestamp":1792587037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jove.com\/t\/70167\/development-validation-rapid-lc-msms-method-for-carfilzomib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":30,"journal-issue":{"issue":"231","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3791\/70167","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]}}}